ProShares Ultra Semiconductors vs Vertex Pharmaceuticals Incorporated — how do they compare? ProShares Ultra Semiconductors trades at $90.13, while Vertex Pharmaceuticals Incorporated trades at $481.09 (market cap $121.95B). Which is the better fit depends on your goals.
| USD | VRTX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $113.53 | $529.59 |
52-Week Low | $39.58 | $366.54 |
Market Cap | — | $121.95B |
Enterprise Value | — | $116.69B |
Trailing returns across standard periods
Latest headlines on both assets
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →